Published in AIDS Weekly, June 24th, 2002
The company also announced that it had submitted U.S. and European regulatory packages to the FDA and EMEA to seek regulatory approvals for D2E7, its anti-TNF agent for rheumatoid arthritis, and that it had been awarded an exclusive, multiyear contract to supply the American Red Cross with six infectious disease tests used to screen blood.
Worldwide sales for the first quarter were $4.189 billion, up 17.7% from $3.560 billion in the first quarter of 2001. Earnings per share for the quarter were 54 cents, meeting the First Call analyst consensus...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.